checkAd
    Hutchison China Meditech Aktie
    18,530
     
    USD
    -1,70 %
    -0,320 USD
    Letzter Kurs 01.06.24 Nasdaq
    18,490
     
    USD
    500 STK
    Geldkurs 31.05.24
    18,530
     
    USD
    100 STK
    Briefkurs 31.05.24
    ISIN: US44842L1035 · WKN: A2AF74 · SYM: HCM · Kaiman-Inseln

    Neueste Nachrichten

    HUTCHMED Highlights Presentations at the 2024 ASCO Annual Meeting
    24.05.24 · globenewswire · Hutchison China Meditech
    HUTCHMED announces retirement of Chairman, appointment of new Chairman and change of members of board committees
    17.05.24 · globenewswire · Hutchison China Meditech
    HUTCHMED Highlights Sovleplenib Phase III ESLIM-01 Study and Hematological Malignancy Programs Data to be Presented at the upcoming EHA2024 Congress
    17.05.24 · globenewswire · Hutchison China Meditech
    HUTCHMED Initiates Phase II/III Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naïve Pancreatic Ductal Adenocarcinoma in Collaboration with Hengrui
    14.05.24 · globenewswire · Hutchison China Meditech
    HUTCHMED Initiates the RAPHAEL Registrational Phase III Trial of HMPL-306 for Patients with IDH1- and/or IDH2-Mutated Relapsed/Refractory Acute Myeloid Leukemia in China
    14.05.24 · globenewswire · Hutchison China Meditech
    HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee
    08.05.24 · globenewswire · Hutchison China Meditech
    HUTCHMED Announces Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer Received by Takeda
    26.04.24 · globenewswire · Hutchison China Meditech
    HUTCHMED Highlights Data to be Presented at AACR Congress 2024
    05.04.24 · globenewswire · Hutchison China Meditech
    HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status
    02.04.24 · globenewswire · Hutchison China Meditech
    HUTCHMED Announces Savolitinib sNDA Accepted in China for Treatment-Naïve or Previously Treated Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC
    28.03.24 · globenewswire · Hutchison China Meditech
    HUTCHMED Initiates Registration Stage of the ESLIM-02 Phase II/III Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China
    22.03.24 · globenewswire · Hutchison China Meditech
    HUTCHMED Reports 2023 Full Year Results and Provides Business Updates
    28.02.24 · globenewswire · Hutchison China Meditech